Stoke Therapeutics, Inc. (Nasdaq: STOK) has announced the initiation of a global Phase 3 registrational study, named EMPEROR, for their lead investigational medicine, zorevunersen, aimed at treating Dravet syndrome. Following successful regulatory alignment with the FDA, EMA, and Japan's PMDA, the study is set to commence in the second quarter of 2025. This strategic move is bolstered by a collaboration with Biogen, which enables commercialization capabilities for rare genetic diseases. Stoke retains exclusive rights in the U.S., Canada, and Mexico, with Biogen covering the rest of the world. The anticipated data readout in the second half of 2027 is expected to support global regulatory filings, positioning zorevunersen as a potential first-in-class disease-modifying treatment for Dravet syndrome.
免責聲明：投資有風險，本文並非投資建議，以上內容不應被視為任何金融產品的購買或出售要約、建議或邀請，作者或其他用戶的任何相關討論、評論或帖子也不應被視為此類內容。本文僅供一般參考，不考慮您的個人投資目標、財務狀況或需求。TTM對信息的準確性和完整性不承擔任何責任或保證，投資者應自行研究並在投資前尋求專業建議。